Latest Period
Q1 2026
Security Snapshot
Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) Institutional Ownership
CUSIP: 74365A309
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
99
Shares (Excl. Options)
16,649,362
Price
$2.17
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- PLX on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 16,649,362
- Total 13F value
- $36,108,032
- Portfolio coverage rank
- 0%
- Share change
- +1,951,572
- Value change
- +$4,420,350
- Number of holders
- 99
- Shares outstanding
- 80,361,978
- SEC-reported price per share
- $1.93
- Insider filing price
- $1.93
Latest holder snapshot
5 signals
Issuer context
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PLX - Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 74365A309.
- 99 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 82 to 99 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $26,832,150 to $36,108,032.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 99 institutions filings for Q1 2026.
Security key
74365A309
Latest holder period
Q1 2026
13F holders
99
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
PLX full holder history
Protalix BioTherapeutics, Inc. SEC filings
Protalix BioTherapeutics, Inc. company facts
Protalix BioTherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74365A309:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
PLX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MAK Capital Fund LP | 4.5% | -22% | $11,355,147 | -$3,244,593 | 3,616,289 | -22% | MAK Capital Fund LP | 24 Mar 2026 |
As of 31 Mar 2026, 99 institutional investors reported holding 16,649,362 shares of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX). This represents 21% of the company’s total 80,361,978 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
19%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4.5% | 3,616,962 | -0.83% | 0% | $7,848,807 |
| MAK CAPITAL ONE LLC | 4.4% | 3,544,139 | 1.3% | $7,690,782 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.5% | 1,224,800 | -3% | 0% | $2,657,816 |
| STATE STREET CORP | 1.2% | 972,815 | +66% | 0% | $2,111,009 |
| NORTHERN TRUST CORP | 1.1% | 885,448 | +2.3% | 0% | $1,921,422 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 865,298 | +4.2% | 0% | $1,877,696 |
| Stratos Wealth Partners, LTD. | 0.62% | 500,000 | 0% | 0.01% | $1,085,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.54% | 432,485 | 0% | 0% | $938,492 |
| Prospera Financial Services Inc | 0.52% | 418,570 | 0.01% | $908,272 | |
| Opaleye Management Inc. | 0.42% | 340,000 | -86% | 0.1% | $737,800 |
| MORGAN STANLEY | 0.38% | 301,793 | +129% | 0% | $654,890 |
| DIMENSIONAL FUND ADVISORS LP | 0.37% | 296,843 | +933% | 0% | $643,789 |
| UBS Group AG | 0.33% | 265,535 | +1.1% | 0% | $576,211 |
| GOLDMAN SACHS GROUP INC | 0.31% | 251,345 | -4.4% | 0% | $545,418 |
| Bank of New York Mellon Corp | 0.27% | 219,307 | +4% | 0% | $475,896 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.26% | 207,275 | -11% | 0% | $449,787 |
| Round Rock Advisors LLC | 0.24% | 192,080 | +24% | 0.06% | $416,814 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.24% | 189,100 | 0% | 0.01% | $410,347 |
| EVERGREEN CAPITAL MANAGEMENT LLC | 0.21% | 171,338 | 0% | 0.01% | $371,804 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.2% | 159,311 | -9% | 0% | $345,705 |
| Diametric Capital, LP | 0.15% | 124,195 | -11% | 0.07% | $269,503 |
| Nuveen, LLC | 0.11% | 90,188 | 0% | 0% | $195,708 |
| LAZARD ASSET MANAGEMENT LLC | 0.11% | 86,617 | +21% | 0% | $187,959 |
| BANK OF AMERICA CORP /DE/ | 0.1% | 79,079 | +71% | 0% | $171,601 |
| DEUTSCHE BANK AG\ | 0.09% | 74,985 | +8763% | 0% | $162,717 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
Q1 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 16,649,362 | $36,108,032 | +$4,420,350 | $2.17 | 99 |
| 2025 Q4 | 14,904,284 | $26,832,150 | +$1,854,272 | $1.80 | 82 |
| 2025 Q3 | 13,927,352 | $30,914,125 | +$4,618,112 | $2.22 | 76 |
| 2025 Q2 | 11,908,531 | $17,628,861 | +$1,905,095 | $1.48 | 62 |
| 2025 Q1 | 8,186,092 | $20,953,817 | +$9,615,818 | $2.56 | 63 |
| 2024 Q4 | 4,467,337 | $8,398,680 | +$2,201,784 | $1.88 | 46 |
| 2024 Q3 | 3,383,529 | $3,451,053 | -$2,253,845 | $1.02 | 43 |
| 2024 Q2 | 5,625,789 | $6,582,396 | -$4,774,740 | $1.17 | 64 |
| 2024 Q1 | 9,445,037 | $11,900,614 | -$696,249 | $1.26 | 61 |
| 2023 Q4 | 9,848,515 | $17,531,878 | +$1,241,481 | $1.78 | 65 |
| 2023 Q3 | 9,166,276 | $15,209,597 | -$97,896 | $1.66 | 61 |
| 2023 Q2 | 8,974,519 | $17,902,094 | +$11,998,091 | $2.00 | 66 |
| 2023 Q1 | 2,937,638 | $6,146,705 | +$447,739 | $2.10 | 34 |
| 2022 Q4 | 3,567,822 | $4,870,646 | +$111,553 | $1.37 | 26 |
| 2022 Q3 | 3,548,189 | $3,696,081 | +$2,398,630 | $1.04 | 26 |
| 2022 Q2 | 1,193,025 | $1,298,298 | +$25,721 | $1.09 | 27 |
| 2022 Q1 | 1,217,014 | $1,287,936 | -$1,765,451 | $1.06 | 28 |
| 2021 Q4 | 2,921,778 | $2,436,675 | -$1,654,962 | $0.83 | 24 |
| 2021 Q3 | 4,412,957 | $5,908,463 | +$92,750 | $1.33 | 32 |
| 2021 Q2 | 4,315,299 | $8,240,101 | -$19,328,651 | $1.91 | 31 |
| 2021 Q1 | 8,821,889 | $39,349,366 | +$21,195,496 | $4.46 | 36 |
| 2020 Q4 | 4,087,703 | $14,838,993 | -$3,209,332 | $3.63 | 22 |
| 2020 Q3 | 4,761,719 | $18,443,257 | -$1,925,407 | $3.87 | 23 |
| 2020 Q2 | 5,260,461 | $19,818,169 | -$2,815,871 | $3.79 | 26 |
| 2020 Q1 | 5,996,154 | $14,097,585 | +$12,574,926 | $2.35 | 14 |